ClinicalTrials.gg

Program

rondecabtagene autoleucel

Also written as “Rondecabtagene autoleucel (ronde-cel)”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell, led by Lyell Immunopharma.

Furthest: phase 3, since Sep 16, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lyell Immunopharma22 open or runningphase 3since Sep 16, 2025Mar 24, 2023Dec 31, 2028phase 2 · NCT05826535

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2023First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT05826535 · 270 planned · United States, Australia
  2. Sep 16, 2025Phase 3 study in Lymphoma, B-CellNCT07188558 · 400 planned · United States, Australia, Canada

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05826535
  2. Dec 2029Primary completion: phase 3 study in Lymphoma, B-CellNCT07188558

TargetBeta

CD19 →MS4A1 →read by rule
“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 23
prizloncabtagene autoleucelruleAbelZetaphase 22
GSK5926371GlaxoSmithKlinephase 22
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleavencell-therapeutics-incphase 21
CT204V-CD19 × CD20ruleAstraZenecaphase 21
HB2198rulehinge-biophase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07188558Lymphoma, B-Cell · United States, Australia, Canada3RecruitingDec 2029400
NCT05826535Lymphoma, Non-Hodgkin · United States, Australia2RecruitingDec 31, 2028270

How it is read

Names in the registry

  • “rondecabtagene autoleucel”, 1 entry
  • “Rondecabtagene autoleucel (ronde-cel)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.